2 results
Approved WMOCompleted
To assess indacaterol (300 and 600 ug once daily via SDDPI) superiority in patients with COPD as compared to placebo with respect to 24 h post dose (through) FEV1 after 12 weeks of treatment.
Approved WMORecruiting
ObjectivesPrimary · In Part 1 of the study is to determine the maximum tolerated doses (MTDs) and/or recommended Phase 2 dose (RP2D) of CC-220 as monotherapy (MonoT), in combination with dexamethasone (DEX) (DoubleT), in combination with DEX and…